Newsletters

Please click on a month in the table below for the corresponding newsletter.

Kent & Medway Newsletters

Issues Contents Summary
Issue 52 - November 2023
  • Kent & Medway Medicines Sustainability Re-Hale Project
  • Direct Oral Anticoagulants (DOACs) – A Change to Improve Patient Safety
  • Emollients and fire safety
  • New Melatonin Guidelines in Kent and Medway
  • Gastro-intestinal Anti-spasmodic Prescribing
  • New Position Statement: Safe Prescribing of Injectable Medicines in Primary Care
  • Addition of Actimorph orodispersible morphine to formularies and new Morphine Sulfate Liquid Guidance
  • Addition of Methenamine Hippurate to the Kent and Medway Formulary
  • Nitrofurantoin MHRA Drug Safety Update – New Supporting guidance for patients and prescribers
  • Wegovy and risks of inadvertent prescribing and dispensing of injectable semaglutide
  • Kent and Medway guidance on Emollient Prescribing
  • MHRA Drug Safety Update
  • Shortages Summary
Issue 53 - December 2023
  • Licensing of anastrozole for primary prevention of breast cancer
  • Valproate: organisations to prepare for new regulatory measures for oversight of prescribing to new patients and existing female patients
  • New Dementia Guidelines in Kent and Medway
  • Kent and Medway List of New Approved Guidelines
  • NIHR Evidence Webinar 30th January 2024: How can we reduce antibiotic use in primary care?
  • Potential for inappropriate dosing of insulin when switching insulin degludec (Tresiba) products
  • Potential contamination of some carbomer-containing lubricating eye products with Burkholderia cenocepacia - measures to reduce patient risk
  • MHRA Drug Safety Update
  • NICE News December 2023
  • Medicine Supply Notification: Bumetanide 1mg and 5mg tablets
  • ADHD medicines supply disruption update
  • Shortages Summary
Issue 54 - January 2024
  • Antibiotic Course Length
  • Interaction of tramadol and warfarin
  • Pregabalin and risk in pregnancy / Gabapentinoid prescribing
  • FreeStyle Libre 3
  • Kent and Medway List of New Approved Guidelines
  • MHRA Drug Safety Update
  • Update to the NPSA on GLP-1 RAs
    Shortages
Issue 55 - February 2024
  • Mounjaro®▼ (tirzepatide) KwikPen® solution for injection
  • Wegovy® (semaglutide) solution for injection for Weight Management
  • Trurapi® (insulin aspart) 100units/ml solution for injection
  • Fezolinetant (Veoza®) – not for NHS prescribing
  • Prescribing of Armour Thyroid and other unlicensed desiccated thyroid extract (DTE) products
  • Gluten Free Prescribing in Kent and Medway
  • Reducing OTC Prescriptions in Primary Care
  • East Kent HCP – KCHFT pilot: mucolytic drug holiday initiative
  • MHRA Press Release – Pioneering genetic biobank to start recruiting patients on stroke prevention medicines
  • MHRA Drug Safety Update – January 2024
  • NICE News – February 2024
  • Shortages Summary
  • Shortage of Tegretol 200mg and 400mg prolonged release tablets
  • ADHD medication availability and supply disruption update
  • Riluzole availability
Issue 56 - March 2024
  • Kent and Medway Dry Eye Guidance - updated
  • Reducing ONS Starter Pack Prescriptions in Primary Care
  • Prescribing of DPP-4 inhibitors (gliptins) – reminder that sitagliptin is 1st line choice
  • Daridorexant for treating long-term insomnia
  • Impact of C. Difficile Infections and Management Update – 2nd May 2024
  • LMWH Prescribing Pathways in East Kent
  • Sharps Bin Provision - Swale Borough Council
  • MHRA Drug Safety Update February 2024
  • Shortages Summary
  • Shortage of Rasagiline 1mg tablets (March 2024)
Issue 57 - April 2024
  • Glaucoma – Generic prescribing
  • Eye supplements - Lutein and Antioxidants
  • Reminder: Eye Lid Hygiene
  • Continence and stoma appliances - Ordering process reminder
  • ScriptSwitch® Quantity Limit Switches
  • PITstop diabetes on-demand videos
  • New SPS Resource – Managing Interactions with Direct Oral Anticoagulants (DOACs)
  • BNF Interaction Update: Tramadol – Warfarin Interaction
  • MHRA Drug Safety Update March 2024
  • NICE News – April 2024
  • NHS England: Puberty Suppressing Hormones for Children and Adolescents with Gender Incongruence
  • Shortages Summary
  • ADHD medication availability and supply disruption update
  • Discontinuations of Insulatard® InnoLet® and Levemir InnoLet® 3ml pre-filled disposable devices
Issue 58 - May 2024
  • Adding “Hospital/specialist” medications to a patient’s medication screen on EMIS
  • Reminder – MHRA Drug Safety Update 19 April 2022. Pregabalin (Lyrica): findings of safety study on risks during pregnancy
  • Kent and Medway List of New Approved Guidelines from Integrated Medicines Optimisation Committee (IMOC) April 2024
  • Obtaining Anticoagulant alert cards and DOAC booklets
  • Methadone Prescribing
  • Cost-effective Prescribing of Macrogol Oral Powder Sachets
  • PrescQIPP Clinical Masterclass webinars
  • UTI diagnostic quick reference tool review consultation - closes 2 June
  • MHRA Drug Safety Update
  • Shortages Update
Issue 59 - June 2024
  • Eprex to Retacrit switch - Message from East Kent Hospitals UFT for GP Practices
  • Reminder – Ongoing GLP-1 RA Supply Issues
  • GLP-1 RAs for Weight Management / The risks of inadvertent prescribing and dispensing of injectable semaglutide (Wegovy®& Ozempic®)
  • EasyChamber® spacer devices
  • MORPh webinar: SMRs & Medicines Optimisation and Sustainability in Respiratory Care
  • Pharmacy First
  • Reminder for East Kent Practices – Hospital Only Formulary status for Trimetazidine and Sucralfate
  • National Patient Safety alert: Shortage of Pancreatic enzyme replacement therapy (PERT)
  • MHRA Drug Safety Update – May 2024
  • NICE News – June 2024
  • Shortages Summary
Issue 60 - July 2024
  • Clozapine prescribing
  • Assessment of a pharmacist’s ability to interpret, review, and action CYP2C19 pharmacogenetic reports and obtain pharmacist’s views on the reporting structure – Deadline 26th July 2024.
  • Best Practice Guidance (BPG) for Care Homes
  • National Patient Safety – Improvement Programmes
  • TARGET Antibiotics – Prescribing in Primary Care
  • Webinar: Paediatric antimicrobial prescribing in primary care
  • Kent and Medway List of New Approved Guidelines
  • MHRA Drug Safety Update
  • Shortages summary
Issue 61 - August 2024
  • Ongoing GLP-1 RA Supply Issues – Quantities and Incidents
  • FreeStyle Libre 3
  • Clozapine Fact Sheet for Primary Care Clinicians
  • An Update on Metolazone (Xaqua®) Prescribing in Kent and Medway ICB
  • OpenPrescribing Webinar for Primary Care Teams
  • Polypharmacy: Medicines and the Risk of Falls in Older People Lunchtime Masterclass
  • MHRA Drug Safety Update – July 2024
  • NICE News – August 2024
  • Specialist Pharmacy Service (SPS) support for medicines shortages - PERT
  • Shortages Summary
Issue 62 - September 2024
  • 2024-2045 Medicines Optimisation Quality, Innovation, Productivity and Prevention (Previous MOS Scheme)
  • Learning from Near Misses during Anticoagulant switching
  • GP Practice Support For Patients Under Early Release Scheme
  • Valproate Use in Men: Contraception Use
  • PrescQipp Prescribing Mastery Webinars
  • MHRA Drug safety Update
  • Shortages Summary
Issue 63 - October 2024
  • Topiramate- Implementing MHRA Safety Measures in Kent & Medway
  • Antimicrobial Prescribing Guidance
  • Reporting a Controlled Drug Issue
  • Home Use of Nebulised asthma rescue therapy in children
  • Salbutamol SPC update
  • The adult attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD) service
  • REMINDER: Prescribe Apixaban generically
  • ScriptSwitch® Prescribing - GP Prescriber Knowledge Centre
  • Chlordiazepoxide possible genotoxicity risk and KMPT Alcohol Detox policy update
  • Update on the Supply of Semaglutide Injections (Ozempic®) & Prescribing of Tirzepatide Injections (Mounjaro®)
  • Ardens Resources for SGLT2i
  • Hydroxycarbamide with Continuous Glucose Monitoring Systems
  • New RPS and RCGP Repeat Prescribing Toolkit will improve safety and efficiency
  • MHRA Drug Safety Update
  • Shortages Summary
  • NICE News Bimonthly – Oct 2024
Issue 64 - November 2024
  • Kent and Medway ICB Pain Services Community of Practice Webinar
  • Rivaroxaban – generic available – All DOACs MUST be prescribed generically
  • Independence Wound Protection and Collection Pouches (VAP range) – Non formulary items
  • Reminder – Kent and Medway ICB Forceval® capsules Position Statement
  • Opioids- Safer Prescribing and Preferred Cost-effective Brands. Information for General Practice
  • MHRA Drug Safety Update – October 2024
  • Shortages Summary
  • Discontinuation NovoRapid® (insulin aspart) FlexTouch® 100units/ml solution for injection 3ml pre-filled pens
  • Reminder for East Kent Practices – Oral Morphine Prescribing Resources

Please note that newsletters are archived after 12 months to avoid offering out-of-date information.